Ravit Arav-Boger.

0 times the odds of experiencing improved hearing or safety of normal hearing at 12 weeks and 2.6 times the odds at 24 months. The calculation of the price ratio showed that among participants with CNS involvement at baseline, those in the 6-month group acquired a 65 percent greater likelihood of having better outcomes from baseline to 12 weeks than those in the 6-week group and a 46 percent greater probability of having better outcomes from baseline to 24 months than those in the 6-week group. Among individuals without CNS involvement, the corresponding values were 22 percent and 19 percent.